Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This is a single-arm, single-dose dose-escalation and dose-expansion study.
Leukemia, Myeloid, Acute
BIOLOGICAL: BG1805
Dose Limited Toxicity Rate, After the infusion of BG1805, subjects still experienced adverse events, meeting the DLT definition, related to or possibly related to BG1805 infusion after optimal supportive treatment., Up to 28 days after BG1805 infusion.|Incidence of Treatment-Emergent Adverse Events, Count the Incidence of adverse events., Up to 24 months.
Concentration of CAR-T cells after Infusion (PK), CAR-T in peripheral blood after infusion, Up to 24 months.|overall response rate, ORR, Defined as the proportion of subjects achieving complete response(CR), complete remission with incomplete blood cell recovery (CRi), morphologic leukemia-free state (MLFS), or partial response(PR)., Up to 24 months.|Concentration of Cytokine after Infusion (PD), Calculate the change of cytokine concentration in peripheral blood after After BG1805 infusion. Cytokines include IL-2„ÄÅIL-6 and so on., Up to 24 months.
Patients with relapsed/refractory acute myeloid leukemia (r/r AML) were enrolled in the trial, which was divided into two parts: dose-escalation phase and dose-expansion phase.